University Hospital of Crete
60
5
6
32
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
33.3%
20 terminated/withdrawn out of 60 trials
61.5%
-25.0% vs industry average
28%
17 trials in Phase 3/4
0%
0 of 32 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (60)
Opioid Free Anesthesia-Analgesia Strategy and Surgical Stress in Elective Open Abdominal Aortic Aneurysm Repair
Role: collaborator
Physical Activity Component of the Greek Interventional Geriatric Study to Prevent Cognitive Impairment and Disability (GINGER)
Role: collaborator
A Randomized Controlled Trial Comparing Fat-free Versus Balanced (WHO) Diet in Gallstone Disease
Role: lead
Malnutrition Assessment Tools in Surgery
Role: lead
BenRalizumab Effect on Airway Remodeling in Severe asTHma
Role: collaborator
Electroacupuncture Pain Treatment, Mechanical Hyperalgesia, Quality of Life & Expression of Mu+ B Cells in Fibromyalgia
Role: collaborator
Hellenic Registry of Ovation Alto™ Abdominal Stent Graft System
Role: collaborator
Evaluation of Surgical Risk Prediction Tools.
Role: lead
Longitudinal Assessment of Clinical Course and BIOmarkers in Severe Chronic AIRway Disease
Role: collaborator
Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer
Role: collaborator
Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer
Role: collaborator
Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer
Role: collaborator
Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer
Role: collaborator
A New Formulation of Intravenous Paracetamol for Fever Management
Role: collaborator
Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer
Role: collaborator
Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc
Role: lead
Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment
Role: lead
Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer
Role: lead
Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer
Role: lead
Lapatinib and Circulating Tumor Cells in Breast Cancer
Role: lead